3 completed, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow vadimezan: new trials by email Literature Review of vadimezan trials Research Report on vadimezan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Docetaxel, ASA404 - Urothelial Carcinoma | Phase 2 | Withdrawn | Hoosier Cancer Research Network | 2010-06-01 | 2015-08-19 | |
| Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer carboplatin, paclitaxel, vadimezan - Lung Cancer | Phase 2 | Completed | Swiss Cancer Institute | 17 | 2010-01-01 | 2013-04-10 |
| Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer AS1404 (DMXAA) - Prostate Cancer | Phase 2 | Completed | Antisoma Research | 70 | 2005-05-01 | 2009-01-30 |
| Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer DMXAA in combination with carboplatin and paclitaxel - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Antisoma Research | 105 | 2004-09-01 | 2009-01-30 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Prostatic Neoplasms (1)
Antisoma Research (2) · Hoosier Cancer Research Network (1) · Swiss Cancer Institute (1)
Switzerland (1) · United States (1)
Mark McKeage (1) · Martin Frueh, MD (1) · Matthew Galsky, M.D. (1) · Miklos Pless, MD (1) · Oliver Gautschi, MD (1) · Roberto Pili, MD (1)